New therapies show promise in treating diabetes New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes. Large variety of multiple myeloma treatment options presents challenges December 06, 2016 By Bryant Furlow There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study Insurer: No more prior auths for opioid addiction meds October 28, 2016 By Tracey Walker As part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder. Copay assistance programs: Managed care pros and cons Do copay assistance program offer a long-term solution for patients? Experts weigh in. Three ways to rein in drug costs regardless of who becomes president October 13, 2016 By Marc O'Connor It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation. PDMPS: An effective but underutilized resource for prescribers October 11, 2016 By Tracey Walker MCOs are going to have to step up their efforts to impact the growing opioid epidemic in this country. Biosimilars and interchangeable biologics: News to watch October 06, 2016 By Aubrey Westgate Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain. Nearly half of BCBS members discontinue this RA drug after 1 year October 06, 2016 By Tracey Walker Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments. Biomarkers: Top challenges and opportunities in managed care October 05, 2016 By Aubrey Westgate Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain. Five specialty pharmaceutical trends to watch October 05, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.